Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer

Frontiers in Physiology

Volumn 4 NOV, Issue , 2013, Pages

  Hamada, Shin ^a   Masamune, Atsushi ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Cell survival; Chemoresistance; Desmoplasia; Pancreatic stellate cells; Sonic hedgehog inhibitor

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; ANGIOTENSIN RECEPTOR ANTAGONIST; APOCYNIN; CANDESARTAN; CONNECTIVE TISSUE GROWTH FACTOR; CURCUMIN; CYCLOPAMINE; DENDRITIC CELL VACCINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; DNA VACCINE; ELLAGIC ACID; FG 3019; GEMCITABINE; LOSARTAN; OLMESARTAN; PACLITAXEL; POLYPHENOL; SARIDEGIB; SONIC HEDGEHOG PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CELL INTERACTION; CHRONIC PANCREATITIS; DNA IMMUNIZATION; DRUG POTENTIATION; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; IMMUNE DEFICIENCY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

EID: 84889651721     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00331     Document Type: Review

References (67)

1. Abreu, J. G., Ketpura, N. I., Reversade, B., and De Robertis, E. M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4, 599-604. doi: 10.1038/ncb826
2. Alvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megias, D., Guerra, C., et al. (2013). Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926-933. doi: 10.1038/bjc.2013.415
3. Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., et al. (2004). Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29, 179-187. doi: 10.1097/00006676-200410000-00002
4. Bachem, M. G., Schunemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A., et al. (2005). Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907-921. doi: 10.1053/j.gastro.2004.12.036
5. Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T., et al. (2008). Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995-6004. doi: 10.1158/1078-0432.CCR-08-0291
6. Bennewith, K. L., Huang, X., Ham, C. M., Graves, E. E., Erler, J. T., Kambham, N., et al. (2009). The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69, 775-784. doi: 10.1158/0008-5472.CAN-08-0987
7. Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., and Benson, A. B. 3rd. (2002). Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20, 3270-3275. doi: 10.1200/JCO.2002.11.149
8. Burris, H. A. 3rd. Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
9. Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516. doi: 10.1038/ncomms3516
10. Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., and Vonderheide, R. H. (2007). Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518-9527. doi: 10.1158/0008-5472.CAN-07-0175
11. Egawa, S., Toma, H., Ohigashi, H., Okusaka, T., Nakao, A., Hatori, T., et al. (2012). Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas 41, 985-992. doi: 10.1097/MPA.0b013e318258055c
12. Erkan, M., Adler, G., Apte, M. V., Bachem, M. G., Buchholz, M., Detlefsen, S., et al. (2012). StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut 61, 172-178. doi: 10.1136/gutjnl-2011-301220
13. Erkan, M., Kleeff, J., Gorbachevski, A., Reiser, C., Mitkus, T., Esposito, I., et al. (2007). Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132, 1447-1464. doi: 10.1053/j.gastro.2007.01.031
14. Evans, A., and Costello, E. (2012). The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front. Physiol. 3:270. doi: 10.3389/fphys.2012.00270
15. Gao, R., and Brigstock, D. R. (2006). A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut 55, 856-862. doi: 10.1136/gut.2005.079178
16. Ghansah, T., Vohra, N., Kinney, K., Weber, A., Kodumudi, K., Springett, G., et al. (2013). Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol. Immunother. 62, 1083-1091. doi: 10.1007/s00262-013-1407-9
17. Goodman, K. A., and Hajj, C. (2013). Role of radiation therapy in the management of pancreatic cancer. J. Surg. Oncol. 107, 86-96. doi: 10.1002/jso.23137
18. Hamada, S., Masamune, A., Takikawa, T., Suzuki, N., Kikuta, K., Hirota, M., et al. (2012). Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 421, 349-354. doi: 10.1016/j.bbrc.2012.04.014
19. Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schonekas, H., Rost, A., et al. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946-3952. doi: 10.1200/JCO.2005.05.1490
20. Heinemann, V., Reni, M., Ychou, M., Richel, D. J., Macarulla, T., and Ducreux, M. (2013). Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat. Rev. doi: 10.1016/j.ctrv.2013.04.004. [Epub ahead of print].
21. Heng, E. C., Huang, Y., Black, S. A. Jr., and Trackman, P. C. (2006). CCN2, connective tissue growth factor, stimulates collagen deposition by gingival fibroblasts via module 3 and alpha6- and beta1 integrins. J. Cell. Biochem. 98, 409-420. doi: 10.1002/jcb.20810
22. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schuller, J., et al. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the Central European cooperative oncology group. J. Clin. Oncol. 25, 2212-2217. doi: 10.1200/JCO.2006.09.0886
23. Hidalgo, M. (2010). Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617. doi: 10.1056/NEJMra0901557
24. Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483. doi: 10.1016/j.ccr.2005.04.023
25. Ibrahim, N. K., Desai, N., Legha, S., Soon-Shiong, P., Theriault, R. L., Rivera, E., et al. (2002). Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044.
26. Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., et al. (2011). Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 121, 4106-4117. doi: 10.1172/JCI42754
27. Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., et al. (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112-120. doi: 10.1136/gutjnl-2012-302529
28. Jimeno, A., Feldmann, G., Suarez-Gauthier, A., Rasheed, Z., Solomon, A., Zou, G. M., et al. (2009). A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 8, 310-314. doi: 10.1158/1535-7163.MCT-08-0924
29. Kameshima, H., Tsuruma, T., Kutomi, G., Shima, H., Iwayama, Y., Kimura, Y., et al. (2013). Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 104, 124-129. doi: 10.1111/cas.12046
30. Kayed, H., Kleeff, J., Osman, T., Keleg, S., Buchler, M. W., and Friess, H. (2006). Hedgehog signaling in the normal and diseased pancreas. Pancreas 32, 119-129. doi: 10.1097/01.mpa.0000202937.55460.0c
31. Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., et al. (2011). IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757. doi: 10.1172/JCI58814
32. Kikuta, K., Masamune, A., Watanabe, T., Ariga, H., Itoh, H., Hamada, S., et al. (2010). Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 403, 380-384. doi: 10.1016/j.bbrc.2010.11.040
33. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622. doi: 10.1200/JCO.2010.28.1386
34. Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., et al. (2012). Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest. New Drugs 30, 382-386. doi: 10.1007/s10637-010-9526-z
35. Lathers, D. M., Clark, J. I., Achille, N. J., and Young, M. R. (2004). Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 53, 422-430. doi: 10.1007/s00262-003-0459-7
36. Mantoni, T. S., Schendel, R. R., Rodel, F., Niedobitek, G., Al-Assar, O., Masamune, A., et al. (2008). Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol. Ther. 7, 1806-1815. doi: 10.4161/cbt.7.11.6846
37. Masamune, A., Hamada, S., Kikuta, K., Takikawa, T., Miura, S., Nakano, E., et al. (2013). The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand. J. Gastroenterol. 48, 602-609. doi: 10.3109/00365521.2013.777776
38. Masamune, A., Kikuta, K., Satoh, M., Suzuki, N., and Shimosegawa, T. (2005a). Green tea polyphenol epigallocatechin-3-gallate blocks PDGF-induced proliferation and migration of rat pancreatic stellate cells. World J. Gastroenterol. 11, 3368-3374.
39. Masamune, A., Satoh, M., Kikuta, K., Suzuki, N., Satoh, K., and Shimosegawa, T. (2005b). Ellagic acid blocks activation of pancreatic stellate cells. Biochem. Pharmacol. 70, 869-878. doi: 10.1016/j.bcp.2005.06.008
40. Masamune, A., and Shimosegawa, T. (2009). Signal transduction in pancreatic stellate cells. J. Gastroenterol. 44, 249-260. doi: 10.1007/s00535-009-0013-2
41. Masamune, A., and Shimosegawa, T. (2013). Pancreatic stellate cells-multi-functional cells in the pancreas. Pancreatology 13, 102-105. doi: 10.1016/j.pan.2012.12.058
42. Masamune, A., Suzuki, N., Kikuta, K., Satoh, M., Satoh, K., and Shimosegawa, T. (2006). Curcumin blocks activation of pancreatic stellate cells. J. Cell. Biochem. 97, 1080-1093. doi: 10.1002/jcb.20698
43. Masamune, A., Watanabe, T., Kikuta, K., Satoh, K., and Shimosegawa, T. (2008). NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G99-G108. doi: 10.1152/ajpgi.00272.2007
44. Michl, P., and Gress, T. M. (2013). Current concepts and novel targets in advanced pancreatic cancer. Gut 62, 317-326. doi: 10.1136/gutjnl-2012-303588
45. Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., et al. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307. doi: 10.1158/0008-5472.CAN-06-1690
46. Nakai, Y., Isayama, H., Ijichi, H., Sasaki, T., Sasahira, N., Hirano, K., et al. (2010). Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 103, 1644-1648. doi: 10.1038/sj.bjc.6605955
47. Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., et al. (2013a). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 12325-12330. doi: 10.1073/pnas.1300415110
48. Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., et al. (2013b). SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut doi: 10.1136/gutjnl-2013-305559. [Epub ahead of print].
49. Neuzillet, C., Tijeras-Raballand, A., Cros, J., Faivre, S., Hammel, P., and Raymond, E. (2013). Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. doi: 10.1007/s10555-013-9439-3. [Epub ahead of print].
50. Niethammer, A. G., Lubenau, H., Mikus, G., Knebel, P., Hohmann, N., Leowardi, C., et al. (2012). Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 12:361. doi: 10.1186/1471-2407-12-361
51. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461. doi: 10.1126/science.1171362
52. Olson, P., and Hanahan, D. (2009). Cancer. Breaching the cancer fortress. Science 324, 1400-1401. doi: 10.1126/science.1175940
53. O'Reilly, E. M., Niedzwiecki, D., Hall, M., Hollis, D., Bekaii-Saab, T., Pluard, T., et al. (2010). A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 15, 1310-1319. doi: 10.1634/theoncologist.2010-0152
54. Ostrand-Rosenberg, S., and Sinha, P. (2009). Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506. doi: 10.4049/jimmunol.0802740
55. Sakurai, T., Kudo, M., Fukuta, N., Nakatani, T., Kimura, M., Park, A. M., et al. (2011). Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. Pancreatology 11(Suppl. 2), 7-13. doi: 10.1159/000323478
56. Scarlett, C. J. (2013). Contribution of bone marrow derived cells to the pancreatic tumor microenvironment. Front. Physiol. 4:56. doi: 10.3389/fphys.2013.00056
57. Song, J. Y., Kim, C. S., Lee, J. H., Jang, S. J., Lee, S. W., Hwang, J. J., et al. (2013). Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Invest. New Drugs doi: 10.1007/s10637-013-0030-0. [Epub ahead of print].
58. Stanton, B. Z., and Peng, L. F. (2010). Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol. Biosyst. 6, 44-54. doi: 10.1039/b910196a
59. Steding, C. E., Wu, S. T., Zhang, Y., Jeng, M. H., Elzey, B. D., and Kao, C. (2011). The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133, 221-238. doi: 10.1111/j.1365-2567.2011.03429.x
60. Sultana, A., Tudur Smith, C., Cunningham, D., Starling, N., Tait, D., Neoptolemos, J. P., et al. (2007). Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br. J. Cancer 96, 1183-1190. doi: 10.1038/sj.bjc.6603719
61. Sun, J. M., Ahn, M. J., Choi, Y. L., Ahn, J. S., and Park, K. (2013). Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer doi: 10.1016/j.lungcan.2013.08.023. [Epub ahead of print].
62. Takikawa, T., Masamune, A., Hamada, S., Nakano, E., Yoshida, N., and Shimosegawa, T. (2013). miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem. Biophys. Res. Commun. 437, 433-439. doi: 10.1016/j.bbrc.2013.06.097
63. Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554. doi: 10.1200/JCO.2011.36.5742
64. Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., et al. (2008). Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093. doi: 10.1158/0008-5472.CAN-07-2477
65. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117. doi: 10.1038/nature09515
66. Yamada, T., Kuno, A., Masuda, K., Ogawa, K., Sogawa, M., Nakamura, S., et al. (2003). Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J. Pharmacol. Exp. Ther. 307, 17-23. doi: 10.1124/jpet.103.053322
67. Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y. X., Kranz, D. M., et al. (2008). Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68, 1563-1571. doi: 10.1158/0008-5472.CAN-07-5324